Investors



Back

Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering

August 31, 2015 – Göteborg, Sweden and Trevose, Pa., USA – Cortendo AB (publ) [ticker: CORT on NOTC-A], today announced it has filed a registration statement on Form F-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Cortendo AB has applied to list its ordinary shares on The NASDAQ Global Market under the ticker symbol “SBBP.”

BofA Merrill Lynch and Stifel are acting as joint book-running managers of the proposed offering. JMP Securities is acting as lead manager, Roth Capital Partners is acting as co-manager and Arctic Securities is acting as an advisor.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained, when available from: BofA Merrill Lynch, 222 Broadway, New York, New York 10038, Attention: Prospectus Department or by emailing [email protected]; or Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email at [email protected].

A registration statement on Form F-1 relating to the proposed offering has been filed with the Securities and Exchange Commission but has not yet become effective. The shares to be registered may not be sold nor may offers to buy be accepted prior to the time when the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts:

Cortendo AB

Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
[email protected]

Investor Relations
ICR Inc.
Stephanie Carrington
+1 646-277-1282
[email protected]

Sweden
Box 47
SE-433 21 Partille
Tel. / Fax. +46 (0) 31-263010

USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389







© 2020 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V16 03/2020

  • Ireland Address:
    Suite 206, Fitzwilliam Hall
    Fitzwilliam Place, Dublin 2, D02 T292
    Ireland
  • U.S. Address:
    900 Northbrook Drive, Suite 200
    Trevose, PA 19053
    United States

Phone: +1 610-254-9200
[email protected]

Privacy Statement
Compliance Program